Internal Medicine, Gastroenterology · Houston, TX
NPI
1144226515
Since 2005
Specialty
Internal Medicine, Gastroenterology
Code 207RG0100X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6560 Fannin St Ste 1980
Houston, TX, 77030
Phone (713) 799-8300
Groups this clinician bills Medicare through
Medicare paid, 2024
$229K
2,700 services
Medicare patients, 2024
511
Average age 71
Drug cost, 2024
$1.7M
1,885 prescriptions
Company payments, 2025
$82K
From 17 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Victor Ankoma-Sey was code 99232 (hospital e&m - subsequent), 844 times for 90 patients. In total Victor Ankoma-Sey billed 2,700 services in 26 codes, and Medicare paid $229K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 844 | 90 | $67.98 | $57K |
| 99214 Office E&M - Established | Office | 594 | 306 | $96.04 | $57K |
| 99233 Hospital E&M - Subsequent | Facility | 370 | 89 | $102.16 | $38K |
| 76700 Ultrasound - Abdomen and Pelvis | Office | 201 | 167 | $65.18 | $13K |
| 93976 Duplex Scan - Extremity Arteries | Office | 197 | 166 | $80.42 | $16K |
| 91200 Standard X-ray | Office | 155 | 133 | $25.39 | $3,935 |
| 99223 Hospital E&M - Initial | Facility | 89 | 70 | $149.12 | $13K |
| 99204 Office E&M - New | Office | 58 | 58 | $128.72 | $7,466 |
| 43239 Upper GI Endoscopy | Facility | 39 | 38 | $97.71 | $3,811 |
| 99205 Office E&M - New | Office | 30 | 30 | $173.18 | $5,195 |
| 99214 Office E&M - Established | Facility | 21 | 20 | $84.09 | $1,766 |
| 99222 Hospital E&M - Initial | Facility | 16 | 16 | $112.82 | $1,805 |
| G0121 Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 16 | 16 | $198.92 | $3,183 |
By year: 2022 $284K for 3,520 services; 2023 $224K for 2,596 services; 2024 $229K for 2,700 services.
Medicare prescription drug claims, 2024
In 2024, the drug Victor Ankoma-Sey prescribed most often to Medicare patients was Ursodiol, with 230 prescriptions and refills. In total Victor Ankoma-Sey wrote 1,885 Medicare prescriptions that cost $1.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ursodiol Generic | 230 | 517 | 59 | $49K |
| Xifaxan Rifaximin | 226 | 248 | 37 | $789K |
| Vemlidy Tenofovir Alafenamide | 222 | 249 | 25 | $370K |
| Pantoprazole Sodium Generic | 149 | 368 | 58 | $2,887 |
| Lactulose Generic | 100 | 169 | 44 | $6,333 |
| Furosemide Generic | 92 | 211 | 31 | $475 |
| Spironolactone Generic | 85 | 194 | 35 | $1,246 |
| Omeprazole Generic | 65 | 178 | 24 | $1,773 |
| Azathioprine Generic | 65 | 172 | 20 | $3,169 |
| Famotidine Generic | 54 | 138 | 18 | $1,237 |
| Tenofovir Disoproxil Fumarate Generic | 48 | 88 | 12 | $6,139 |
| Constulose Lactulose | 35 | 40 | 12 | $2,210 |
| Prednisone Generic | 33 | 79 | 13 | $292 |
| Ocaliva Obeticholic Acid | 29 | 37 | Under 11 | $252K |
| Linzess Linaclotide | 27 | 55 | Under 11 | $29K |
Brand drugs: 643 claims; generic drugs: 1,242 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Victor Ankoma-Sey $82K ($82K in general payments such as food, travel and fees) from 17 companies. The largest payer was Ipsen Biopharmaceuticals, Inc with $31K.
| Company | Payments | Amount |
|---|---|---|
| Ipsen Biopharmaceuticals, Inc IPN.PA | 29 | $31K |
| Gilead Sciences, Inc. GILD | 39 | $19K |
| Madrigal Pharmaceuticals MDGL | 55 | $16K |
| Abbvie Inc. ABBV | 30 | $15K |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC BHC | 33 | $1,303 |
| Mirum Pharmaceuticals, Inc. MIRM | 5 | $397 |
| Phathom Pharmaceuticals, Inc. PHAT | 1 | $121 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $80.83 |
| Orphalan Inc | 3 | $51.18 |
| Novo Nordisk Inc NVO | 2 | $41.6 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.